Pharma Journalist -

Eisai and Biogen announced that China’s National Medical Products Administration (NMPA) has approved a once-every-four-weeks intravenous (IV) maintenance dosing schedule for LEQEMBI…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved its biologic therapy TREMFYA® (guselkumab) for use in children aged six years and older…
Read More...

Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation to DYNE-251, a therapy in development for Duchenne muscular…
Read More...

Amgen announced a $650 million expansion of its biologics manufacturing facility in Juncos, Puerto Rico, aimed at increasing drug production and integrating advanced technologies. This…
Read More...

Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb) for treating children aged 1 to under 5 years with homozygous…
Read More...

Er-Kim, an international pharmaceutical company focused on commercializing novel therapies across the EMEA region, has entered into a distribution agreement with Sentynl Therapeutics,…
Read More...

Biostar Pharma, the U.S. subsidiary of Beijing Biostar Biopharmaceutical, announced that its core drug candidate, Utidelone, has been granted Orphan Drug Designation (ODD) by the U.S.…
Read More...

Eli Lilly and Company has officially opened its newest Lilly Gateway Labs (LGL) location in San Diego, California, marking an expansion of its shared innovation hubs that support…
Read More...

Synaffix B.V., a Lonza company focused on advancing clinical-stage antibody-drug conjugate (ADC) technologies, has entered into a licensing agreement with South Korea–based…
Read More...

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company based in Allschwil, Switzerland, announced that it has been awarded a contract by the U.S. Biomedical Advanced…
Read More...